KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Assets (2016 - 2025)

Rigel Pharmaceuticals has reported Assets over the past 16 years, most recently at $513.6 million for Q4 2025.

  • For Q4 2025, Assets rose 213.21% year-over-year to $513.6 million; the TTM value through Dec 2025 reached $513.6 million, up 213.21%, while the annual FY2025 figure was $513.6 million, 213.21% up from the prior year.
  • Assets for Q4 2025 was $513.6 million at Rigel Pharmaceuticals, up from $242.5 million in the prior quarter.
  • Over five years, Assets peaked at $513.6 million in Q4 2025 and troughed at $115.3 million in Q3 2023.
  • A 5-year average of $173.4 million and a median of $144.2 million in 2022 define the central range for Assets.
  • Biggest five-year swings in Assets: tumbled 38.02% in 2022 and later soared 213.21% in 2025.
  • Year by year, Assets stood at $167.3 million in 2021, then decreased by 19.75% to $134.3 million in 2022, then dropped by 12.7% to $117.2 million in 2023, then surged by 39.88% to $164.0 million in 2024, then soared by 213.21% to $513.6 million in 2025.
  • Business Quant data shows Assets for RIGL at $513.6 million in Q4 2025, $242.5 million in Q3 2025, and $206.7 million in Q2 2025.